Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Svizzera | Salute | Prodotti farmaceutici | 653,20 Mrd CHF | 88,7x | 1,27 | 710 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Roche Holding | Svizzera | Salute | Prodotti farmaceutici | 216,09 Mrd CHF | 19,2x | -5,94 | 271,40 CHF | 1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,9% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | Svizzera | Salute | Prodotti farmaceutici | 203,66 Mrd CHF | 20,4x | -5,94 | 256,30 CHF | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 180,77 Mrd CHF | 11,9x | 0,14 | 90,26 CHF | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 15,3% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 180,77 Mrd CHF | 11,9x | 0,14 | 90,72 CHF | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Sandoz | Svizzera | Salute | Prodotti farmaceutici | 16,94 Mrd CHF | -2.379,2x | 24,68 | 38,01 CHF | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,3% Rialzo | Fai l’upgrade a Pro+ | |
Siegfried Holding Ltd | Svizzera | Salute | Prodotti farmaceutici | 4,62 Mrd CHF | 35,8x | -2,55 | 1.078 CHF | -2,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,2% Rialzo | Fai l’upgrade a Pro+ | |
Galenica Sante | Svizzera | Salute | Prodotti farmaceutici | 3,76 Mrd CHF | 21,3x | -0,66 | 75,40 CHF | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 0,9% Rialzo | Fai l’upgrade a Pro+ | |
Dottikon Es Holding AG | Svizzera | Salute | Prodotti farmaceutici | 3,27 Mrd CHF | 43,6x | 236,50 CHF | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 44,9% Rialzo | Fai l’upgrade a Pro+ | ||
Joincare Pharmaceutical DRC | Svizzera | Salute | Prodotti farmaceutici | 2,61 Mrd CHF | 14,7x | 4,92 | 7,04 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
COSMO Pharma | Svizzera | Salute | Prodotti farmaceutici | 990,03 Mln CHF | 15,4x | 0,03 | 61,70 CHF | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 42,9% Rialzo | Fai l’upgrade a Pro+ | |
PolyPeptide Group AG | Svizzera | Salute | Prodotti farmaceutici | 931,79 Mln CHF | -35x | -1,65 | 27,75 CHF | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,4% Rialzo | Fai l’upgrade a Pro+ | |
Santhera Pharmaceuticals Holding | Svizzera | Salute | Prodotti farmaceutici | 95,64 Mln CHF | 1,4x | 0,01 | 7,81 CHF | -5,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curatis Holding | Svizzera | Salute | Prodotti farmaceutici | 58,95 Mln CHF | -0,1x | 12,25 CHF | -7,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Spexis | Svizzera | Salute | Prodotti farmaceutici | 1,35 Mln CHF | -0,1x | -0,03 | 0,02 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |